Sauerwein et al., 2021 - Google Patents
Theranostics in boron neutron capture therapySauerwein et al., 2021
View HTML- Document ID
- 6303002226471999518
- Author
- Sauerwein W
- Sancey L
- Hey-Hawkins E
- Kellert M
- Panza L
- Imperio D
- Balcerzyk M
- Rizzo G
- Scalco E
- Herrmann K
- Mauri P
- De Palma A
- Wittig A
- Publication year
- Publication venue
- Life
External Links
Snippet
Boron neutron capture therapy (BNCT) has the potential to specifically destroy tumor cells without damaging the tissues infiltrated by the tumor. BNCT is a binary treatment method based on the combination of two agents that have no effect when applied individually: 10B …
- 229910052796 boron 0 title abstract description 89
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sauerwein et al. | Theranostics in boron neutron capture therapy | |
Hennrich et al. | [68Ga] Ga-PSMA-11: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging of prostate cancer | |
Ballal et al. | First-in-human results on the biodistribution, pharmacokinetics, and dosimetry of [177Lu] Lu-DOTA. SA. FAPi and [177Lu] Lu-DOTAGA.(SA. FAPi) 2 | |
Vahidfar et al. | Theranostic advances in breast cancer in nuclear medicine | |
Awenat et al. | Diagnostic role of 18F-PSMA-1007 PET/CT in prostate cancer staging: a systematic review | |
Hirata et al. | The Roles of hypoxia imaging using 18F-fluoromisonidazole positron emission tomography in glioma treatment | |
Fortuin et al. | Molecular and functional imaging for detection of lymph node metastases in prostate cancer | |
Plichta et al. | Prostate-specific membrane antigen (PSMA) theranostics for treatment of oligometastatic prostate cancer | |
Vorobyeva et al. | Indirect radioiodination of DARPin G3 using N-succinimidyl-para-iodobenzoate improves the contrast of HER2 molecular imaging | |
Hu et al. | Radiosynthesis and preclinical evaluation of bispecific PSMA/FAP heterodimers for tumor imaging | |
Wong et al. | 64Cu-SAR-bombesin PET-CT imaging in the staging of estrogen/progesterone receptor positive, HER2 negative metastatic breast cancer patients: safety, dosimetry and feasibility in a Phase I trial | |
Patterson et al. | Development of a new positron emission tomography tracer for targeting tumor angiogenesis: synthesis, small animal imaging, and radiation dosimetry | |
Abouzayed et al. | Preclinical evaluation of 99mTc-labeled GRPR antagonists maSSS/SES-PEG2-RM26 for imaging of prostate cancer | |
Bragina et al. | Direct intra-patient comparison of scaffold protein-based tracers,[99mTc] Tc-ADAPT6 and [99mTc] Tc-(HE) 3-G3, for imaging of HER2-Positive breast cancer | |
Lundmark et al. | Preclinical characterisation of PSMA/GRPR-targeting heterodimer [68Ga] Ga-BQ7812 for PET diagnostic imaging of prostate cancer: A step towards clinical translation | |
Herrmann et al. | Molecular imaging of tumors using a quantitative T 1 mapping technique via magnetic resonance imaging | |
Marenco et al. | Chemical and physical characterisation of human serum albumin nanocolloids: kinetics, strength and specificity of bonds with 99mTc and 68Ga | |
Liu et al. | Experimental therapy of HER2-expressing xenografts using the second-generation HER2-targeting affibody molecule 188Re-ZHER2: 41071 | |
Brighi et al. | Comparison between [68Ga] Ga-PSMA-617 and [18F] FET PET as Imaging Biomarkers in Adult Recurrent Glioblastoma | |
Liu et al. | Recent advances in imaging agents anchored with pH (Low) insertion peptides for cancer theranostics | |
Csikos et al. | In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [52Mn] Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model | |
Ren et al. | An albumin-binding PSMA ligand with higher tumor accumulation for PET imaging of prostate cancer | |
Ferrari et al. | [18F] fluciclovine vs.[18F] fluorocholine positron emission tomography/computed tomography: a head-to-head comparison for early detection of biochemical recurrence in prostate cancer patients | |
Luo et al. | SPECT imaging with Tc-99m-labeled HYNIC-FAPI-04 to extend the differential time window in evaluating tumor fibrosis | |
Davis et al. | Personalisation of molecular radiotherapy through optimisation of theragnostics |